Vaccination: Spain will administer the AstraZeneca vaccine only to people aged 18 to 55 years
Covid.AstraZeneca and Oxford prepare the second version of their vaccine for autumn
The coronavirus vaccine developed by AstraZeneca and the
University of Oxford
does not appear to protect against mild and moderate illness caused by the South African variant of the coronavirus, the
, citing a study due to be published Monday.
The pharmaceutical company has communicated that the vaccine is equally effective against the
of the coronavirus, according to new scientific evidence released this Friday.
Among the coronavirus variants that are currently of most concern to scientists and public health experts are the so-called
British, South African and Brazilian
, which appear to spread more rapidly than others.
"In this small phase I / II trial, early data have shown limited efficacy against mild disease primarily due to the South African variant B.1.351," said an AstraZeneca spokesperson in response to the FT report.
"However, we have not been able to adequately determine its effect against severe illness and hospitalization since
the subjects were predominantly healthy young adults
According to the criteria of The Trust Project
See links of interest
Quique San Francisco